Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxilofrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.64 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.64 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.64 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.64 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.64 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.57 |
| ▸ | OPRM1 known ✓ | P35372 | 4/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.57 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.57 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.57 |
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.54 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.54 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.50 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.48 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxilofrine SCHEMBL29354826 | 1.00 | KMT2A (0.68) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL14465574 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL147458 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL14153976 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL4256893 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL5173040 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| SCHEMBL23999280 | 0.81 | CYP2D6 (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Pseudoephedrine SCHEMBL118099 | 0.81 | KMT2A (1.00) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| SCHEMBL20690347 | 0.81 | HIF1A (0.56) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Racephedrine SCHEMBL22823 | 0.81 | KMT2A (1.00) | KMT2AMEN1HBBADRA1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306243-B1 | APPLYING TO IN VIVO SURFACE BIOCOMPATIBLE FORMULATION COMPRISING MOMOMER WHICH FORMER POLYMER IN SITU AT PHYSIOLOGIC PH AND BIOCOMPATIBLE PH MODIFIER; ALLOWING TO POLYMERIZE | CLOSURE MEDICAL CORPORATION | 2001-10-23 | — | — | US | claimed |
| US-6143352-A | USEFUL AS BIOMEDICAL AND SURGICAL ADHESIVES, SEALANTS, IMPLANTS AND BIOACTIVE AGENT RELEASE CARRIERS OR MATRICES, | CLOSURE MEDICAL CORPORATION (US) | 2000-11-07 | — | — | US | claimed |
| EP-0767819-A4 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI POINT MEDICAL CORP (US) | 1997-09-24 | — | — | EP | claimed |
| EP-0767819-A1 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI-POINT MEDICAL CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000760-A1 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI-POINT MEDICAL CORPORATION (US) | 1996-01-11 | — | — | WO | claimed |
| EP-1273665-B1 | PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS | DAIICHI FINE CHEM CO LTD (JP) | 2007-05-16 | — | — | EP | disclosed |
| US-20060014940-A1 | Cloning and characterization of slc26a6, slc26a1, and slc26a2 anion exchangers | MOUNT DAVID B | 2006-01-19 | — | — | US | disclosed |
| US-20050176945-A1 | Cloning and characterization of slc26a7 and slc26a9 anion exchangers | MOUNT JR DAVID B (US) | 2005-08-11 | — | — | US | disclosed |
| US-6835559-B2 | Process for the production of optically active β-amino alcohols | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2004-12-28 | — | — | US | disclosed |
| EP-1438942-A1 | An otorhinological drug delivery device | Schering Oy (FI) | 2004-07-21 | — | — | EP | disclosed |
| US-20040091981-A1 | Process for the production of optically active beta-amino alcohols | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| WO-2003074664-A2 | CLONING AND CHARACTERIZATION OF SLC26A7 AND SLC26A9 ANION EXCHANGERS | VANDERBILT UNIVERSITY (US) | 2003-09-12 | — | — | WO | disclosed |
| EP-1273665-A1 | PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS | Daiichi Fine Chemical Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
| US-6306243-B1 | APPLYING TO IN VIVO SURFACE BIOCOMPATIBLE FORMULATION COMPRISING MOMOMER WHICH FORMER POLYMER IN SITU AT PHYSIOLOGIC PH AND BIOCOMPATIBLE PH MODIFIER; ALLOWING TO POLYMERIZE | CLOSURE MEDICAL CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6143352-A | USEFUL AS BIOMEDICAL AND SURGICAL ADHESIVES, SEALANTS, IMPLANTS AND BIOACTIVE AGENT RELEASE CARRIERS OR MATRICES, | CLOSURE MEDICAL CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6055828-A | Treatment methods for glass medical adhesive applicators | CLOSURE MEDICAL CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999033761-A1 | TREATMENT METHODS FOR GLASS MEDICAL ADHESIVE APPLICATORS | CLOSURE MEDICAL CORPORATION (US) | 1999-07-08 | — | — | WO | disclosed |
| EP-0767819-A4 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI POINT MEDICAL CORP (US) | 1997-09-24 | — | — | EP | disclosed |
| EP-0767819-A1 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI-POINT MEDICAL CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000760-A1 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI-POINT MEDICAL CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |